| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/12/2023 | 27.85% | Oppenheimer | $96 → $84 | Maintains | Outperform |
| 08/07/2023 | 40.03% | Roth MKM | → $92 | Upgrades | Neutral → Buy |
| 06/27/2023 | 46.12% | Oppenheimer | → $96 | Reiterates | Outperform → Outperform |
| 06/16/2023 | 33.94% | Citigroup | → $88 | Reiterates | Neutral → Neutral |
| 05/22/2023 | 35.46% | Barclays | → $89 | Initiates Coverage On | → Equal-Weight |
| 05/11/2023 | 46.12% | Oppenheimer | → $96 | Reiterates | Outperform → Outperform |
| 05/11/2023 | 40.03% | Roth MKM | $93 → $92 | Maintains | Neutral |
| 03/27/2023 | 33.94% | Citigroup | $91 → $88 | Maintains | Neutral |
| 03/01/2023 | 59.82% | UBS | → $105 | Upgrades | Neutral → Buy |
| 02/27/2023 | 41.55% | Roth MKM | $104 → $93 | Maintains | Neutral |
| 02/24/2023 | 46.12% | Oppenheimer | $106 → $96 | Maintains | Outperform |
| 10/21/2022 | 38.51% | Citigroup | → $91 | Initiates Coverage On | → Neutral |
| 10/20/2022 | 33.94% | JP Morgan | $97 → $88 | Maintains | Neutral |
| 08/08/2022 | 47.64% | JP Morgan | $90 → $97 | Maintains | Neutral |
| 08/08/2022 | 47.64% | Oppenheimer | $85 → $97 | Maintains | Outperform |
| 07/20/2022 | 21.77% | JP Morgan | $77 → $80 | Maintains | Neutral |
| 02/25/2022 | 29.38% | Oppenheimer | $86 → $85 | Maintains | Outperform |
| 01/26/2022 | 14.16% | B of A Securities | $94 → $75 | Downgrades | Buy → Neutral |
| 07/21/2021 | 35.46% | JP Morgan | $83 → $89 | Maintains | Overweight |
| 07/16/2021 | 15.68% | Roth Capital | $97 → $76 | Maintains | Neutral |
| 07/15/2021 | 15.68% | Roth Capital | $97 → $76 | Maintains | Neutral |
| 02/02/2021 | 52.21% | Roth Capital | $70 → $100 | Maintains | Neutral |
| 01/06/2021 | 30.9% | JP Morgan | → $86 | Downgrades | Overweight → Neutral |
| 07/09/2020 | 24.81% | JP Morgan | → $82 | Upgrades | Neutral → Overweight |
| 10/24/2019 | — | Cowen & Co. | Downgrades | Outperform → Market Perform | |
| 08/23/2019 | 11.11% | UBS | $59 → $73 | Maintains | Neutral |
| 03/06/2019 | — | JP Morgan | Downgrades | Overweight → Neutral |
What is the target price for Ormat Technologies (ORA)?
The latest price target for Ormat Technologies (NYSE: ORA) was reported by Oppenheimer on October 12, 2023. The analyst firm set a price target for $84.00 expecting ORA to rise to within 12 months (a possible 27.85% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ormat Technologies (ORA)?
The latest analyst rating for Ormat Technologies (NYSE: ORA) was provided by Oppenheimer, and Ormat Technologies maintained their outperform rating.
When is the next analyst rating going to be posted or updated for Ormat Technologies (ORA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ormat Technologies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ormat Technologies was filed on October 12, 2023 so you should expect the next rating to be made available sometime around October 12, 2024.
Is the Analyst Rating Ormat Technologies (ORA) correct?
While ratings are subjective and will change, the latest Ormat Technologies (ORA) rating was a maintained with a price target of $96.00 to $84.00. The current price Ormat Technologies (ORA) is trading at is $65.70, which is out of the analyst's predicted range.